Bayesian Hierarchical Methods for Surveillance of Cervical Dystonia Treatments

TL;DR

This study uses Bayesian hierarchical models to compare doses of botulinum toxin B for cervical dystonia, revealing dose-dependent efficacy and patient-specific factors that inform personalized treatment strategies.

Contribution

It introduces a Bayesian framework for analyzing treatment effects and patient heterogeneity in cervical dystonia, advancing personalized medicine approaches.

Findings

Lower doses (5,000 units) showed significant symptom improvement.

Male patients responded better than females.

Patient and site variability highlight need for personalized protocols.

Abstract

Cervical dystonia, a debilitating neurological disorder marked by involuntary muscle contractions and chronic pain, presents significant treatment challenges despite advances in botulinum toxin therapy. While botulinum toxin type B has emerged as one of the leading treatments, comparative efficacy across doses and the influence of demographic factors for personalized medicine remain understudied. This study aimed to: (1) compare the efficacy of different botulinum toxin type B doses using Bayesian methods, (2) evaluate demographic and clinical factors affecting treatment response, and (3) establish a probabilistic framework for personalized cervical dystonia management. We analyzed data from a multicenter randomized controlled trial involving 109 patients assigned to placebo, 5,000 units, or 10,000 units of botulinum toxin type B groups. The primary outcome was the Toronto Western Spasmodic Torticollis Rating Scale measured over 16 weeks. Bayesian hierarchical modeling assessed treatment effects while accounting for patient heterogeneity. Lower botulinum toxin type B doses (5,000 units) showed greater overall Toronto Western Spasmodic Torticollis Rating Scale score reductions (treatment effect: -2.39, 95% Probability Interval: -4.10 to -0.70). Male patients demonstrated better responses (5.2% greater improvement) than female patients. Substantial between-patient variability and site-specific effects were observed, highlighting the need for personalized protocols. The study confirms botulinum toxin type B's dose-dependent efficacy while identifying key modifiable factors in treatment response. Bayesian methods provided nuanced insights into uncertainty and heterogeneity, paving the way for personalized medicine in cervical dystonia management.